Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24259360 | 0.88 | PIK3CG (0.33) | PIK3CG | |
| SCHEMBL24259585 | 0.87 | PIK3CG (0.33) | PIK3CG | |
| SCHEMBL4398054 | 0.85 | PIK3CG (0.35) | PIK3CGAOC3 | |
| SCHEMBL24452460 | 0.83 | HDAC4 (0.41) | PIK3CG | |
| SCHEMBL2869278 | 0.77 | NOTUM (0.40) | AOC3 | |
| SCHEMBL24258725 | 0.77 | TSHR (0.31) | — | |
| SCHEMBL24602575 | 0.77 | PIK3CG (0.39) | PIK3CGCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL10058001 | 0.76 | ALDH1A1 (0.42) | AOC3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL24258991 | 0.75 | TSHR (0.39) | — | |
| SCHEMBL21690696 | 0.74 | CXCR3 (0.31) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | PIK3CG 2055/4885AOC3 3468/4885CHRM2 1186/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | PIK3CG 2055/4885AOC3 3468/4885CHRM2 1186/4885 |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | PIK3CG 2400/4885AOC3 3395/4885CHRM2 354/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | PIK3CG 2055/4885AOC3 3468/4885CHRM2 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.